Skip to main content
Evidence Snapshot

Angiopoietin-1 receptor

CHEMBL4128 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T01:38:43Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4128
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Angiopoietin-1 receptor as ChEMBL target CHEMBL4128, mapped to UniProt Q02763. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Angiopoietin-1 receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4128
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q02763
Angiopoietin-1 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Angiopoietin-1 receptor matters

As of 2026-09-14

Angiopoietin-1 receptor is reviewed as Angiopoietin-1 receptor (UniProt Q02763); Angiopoietin-1 receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 25 approved drugs, 2302 compounds, and 691 assays, with lead potency reaching pChEMBL 9.9.

Disease context
cancer

Angiopoietin-1 receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALTIRATINIB, CEP-11981, FORETINIB.

Start review with cancer because it currently carries approved-linked support. Linked drugs include ALTIRATINIB, CEP-11981, FORETINIB, GLESATINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 6 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 25 approved drugs, 2302 compounds, and 691 assays for this target. The dominant activity type is IC50. CHEMBL4087541 is the current potency anchor at pChEMBL 9.9.

Use CHEMBL4087541 as the tractability anchor when discussing potency (pChEMBL 9.9).

Activity source · ChEMBL 36 via Core Engine
25 approved pChEMBL 9.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Angiopoietin-1 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q02763, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2302
Total Compounds
691
Total Assays
25
Approved Drugs
IC50: 1259.0, KI: 12.0, EC50: 19.0, KD: 157.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4087541
 9.9 IC50 —
No preferred name
CHEMBL4103584
 9.8 IC50 —
No preferred name
CHEMBL4449700
 9.6 IC50 —
No preferred name
CHEMBL4447552
 9.6 IC50 —
No preferred name
CHEMBL3937186
 9.5 IC50 —

Approved Drugs

Structure Compound First Approval
TIVOZANIB
CHEMBL1289494
 2017
REGORAFENIB
CHEMBL1946170
 2012
CABOZANTINIB
CHEMBL2105717
 2012
AXITINIB
CHEMBL1289926
 2012
CRIZOTINIB
CHEMBL601719
 2011
VANDETANIB
CHEMBL24828
 2011
NILOTINIB
CHEMBL255863
 2007
SORAFENIB
CHEMBL1336
 2005
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T01:38:43Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4128